Multiple sclerosis is a chronic inflammatory demyelinating disease which affect central nervous system. Treatment options in multiple sclerosis have expanded considerably in the recent years.
This article deals with new data about clinical activity, influencing of disease progresion among patients treated with ocrelizumab.